Vagus Nerve and Seizures: How VNS Treats Drug-Resistant Epilepsy

The vagus nerve does not cause seizures, but it has become one of the most effective tools for treating them. Vagus nerve stimulation (VNS) has been an FDA-approved therapy for drug-resistant epilepsy since 1997, and nearly three decades of clinical use have refined both the devices and our understanding of how electrical signals travelling up the vagus nerve can raise the brain’s seizure threshold. For the roughly one-third of epilepsy patients whose seizures resist medication, VNS offers a complementary approach that works around the clock without the cognitive side effects of many anticonvulsant drugs.

How VNS Reduces Seizures

The anti-seizure mechanism of VNS relies on the vagus nerve’s role as a sensory highway to the brainstem. Approximately 80 percent of vagal fibres are afferent, carrying information upward. When an implanted VNS device delivers mild electrical pulses to the left cervical vagus nerve, those signals travel to the nucleus tractus solitarius (NTS) in the medulla. The NTS projects to the locus coeruleus, the brain’s primary source of norepinephrine, and to the raphe nuclei, which produce serotonin. Both neurotransmitters raise cortical seizure thresholds and stabilise neuronal excitability. Functional imaging studies show that VNS also modulates the thalamus and limbic structures, desynchronising the aberrant electrical patterns that propagate during seizures.

This mechanism explains why VNS benefits accumulate over time. Unlike a drug that reaches peak concentration within hours, the neuroplastic changes driven by repeated noradrenergic and serotonergic stimulation deepen over months. Many patients see their best seizure reduction 12 to 24 months after implantation.

Current VNS Devices and Closed-Loop Technology

LivaNova manufactures the FDA-approved VNS Therapy system, with the SenTiva generator being the most recent platform. A pulse generator roughly the size of a stopwatch is implanted beneath the left collarbone and connected to a lead wrapped around the left cervical vagus nerve. The left side is chosen specifically because it carries fewer cardiac efferent fibres than the right, minimising heart rate effects.

Standard VNS delivers stimulation on a programmed duty cycle, typically 30 seconds on and 5 minutes off. The more significant advance is AutoStim, a closed-loop feature that detects sudden heart rate increases (ictal tachycardia) that often accompany seizures and delivers an additional burst of stimulation in response. A 2024 study of 75 patients with drug-resistant epilepsy using closed-loop VNS responding to ictal tachycardia showed improved seizure outcomes compared to standard open-loop programming. Patients can also trigger on-demand stimulation by swiping a magnet over the generator when they feel an aura.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Clinical Effectiveness

Across large registries and long-term follow-up studies, VNS produces a 50 percent or greater reduction in seizure frequency in approximately half of treated patients. Around 5 to 8 percent achieve seizure freedom. While these numbers are modest compared to a successful surgery like temporal lobectomy, VNS is far less invasive and does not carry the risk of neurological deficit. It is most commonly recommended for patients who are not candidates for resective surgery or who have multifocal or generalised epilepsy.

The therapy is approved for patients aged 4 and older with partial-onset seizures that are refractory to medication. Off-label use in generalised epilepsy syndromes, including Lennox-Gastaut and Dravet syndrome, has also shown benefit in paediatric case series.

Vasovagal Syncope: When the Vagus Nerve Mimics a Seizure

Vasovagal syncope (a faint triggered by a vagal surge) can look strikingly similar to a seizure. During a vasovagal episode, abrupt parasympathetic activation causes bradycardia and peripheral vasodilation, dropping blood pressure and cerebral perfusion. The resulting loss of consciousness can include brief myoclonic jerks, eye rolling, and even urinary incontinence, all of which mimic epileptic seizures. Studies suggest that up to 20 percent of patients initially diagnosed with epilepsy actually have reflex syncope.

The distinction matters clinically. Vasovagal syncope typically has a clear trigger (prolonged standing, pain, heat, emotional distress), a prodrome of nausea and tunnel vision, and rapid recovery with lying flat. Seizures more often begin without warning, involve rhythmic tonic-clonic movements lasting over 30 seconds, and produce postictal confusion. When the diagnosis is unclear, tilt-table testing and video-EEG monitoring can differentiate them.

Side Effects and Safety of VNS

The most common side effects of VNS are stimulation-related: hoarseness or voice alteration (the recurrent laryngeal nerve runs alongside the vagus), throat tingling, coughing, and mild dyspnoea during the on phase of the duty cycle. These effects are generally well tolerated, and most patients adapt within weeks. Serious adverse events related to implantation occur in approximately 3 to 4 percent of cases, consistent with the ANTHEM-HFrEF trial’s 3.5 percent 90-day rate for device-related serious events.

VNS does not impair cognition, which is a significant advantage over many anticonvulsant medications. Some patients report mood improvement as an additional benefit, consistent with the device’s separate FDA approval for treatment-resistant depression.

The Future: Precision Stimulation

Research is moving toward more targeted VNS approaches. Closed-loop systems that detect seizure biomarkers beyond heart rate, including EEG-integrated algorithms and vagal nerve compound action potential recordings, are in development. Non-invasive transcutaneous VNS (tVNS) is also being investigated for epilepsy, although current evidence is weaker than for implanted devices. The SPARC initiative’s microCT mapping of vagal fibre organisation may ultimately enable selective fibre stimulation, activating only the afferent pathways relevant to seizure control while avoiding efferent fibres that cause voice changes.

Want to understand how the vagus nerve connects your brain to every major organ system, and why that matters for conditions from epilepsy to inflammation? Get My Vagus Nerve & Me eBook for a clear, science-backed guide to this remarkable nerve.